Retatrutide Side Effects: What Clinical Trials Report — Clinic Retatrutide
Retatrutide side effects documented in Phase 2 and Phase 3 clinical trial data are primarily gastrointestinal — nausea, vomiting, diarrhea, and constipation — consistent with the GLP-1 receptor agonist class. Events were predominantly mild to moderate in severity and were most frequent during dose escalation phases. Serious adverse events occurred at low frequency and were broadly comparable to placebo at lower doses. This page summarizes the safety data from published Phase 2 studies and Phase 3 TRIUMPH-1 topline results.
Retatrutide Safety Profile in Clinical Trials
Phase 2 obesity trial (Jastreboff 2023, NEJM): GI adverse events dominated the safety profile across all active dose arms. Rates were dose-dependent: higher doses generated more frequent GI events during the titration period, which attenuated with continued use at maintenance dose [1].
Phase 2 T2D trial (Rosenstock 2023, Lancet): GI adverse events occurred in 35% (67/190) of retatrutide participants in pooled Phase 2 analyses. No severe hypoglycemia was observed in any Phase 2 arm. Serious adverse events were low-frequency and comparable to placebo at lower doses [2].
A systematic review and meta-analysis of three Phase 2 RCTs (878 patients, Katsi-group 2025 PMC) confirmed: GI events were the primary adverse effect; no major thyroid, pancreatic, or cardiovascular safety signals were identified in Phase 2 human data [20].
Phase 3 TRIUMPH-1 topline (Lilly 2025): all three dose arms met primary and key secondary endpoints. Discontinuation due to adverse events: 4.1% (4 mg), 6.9% (9 mg), 11.3% (12 mg) versus 4.9% placebo. GI events were the primary driver of discontinuations [17].
Onset and Timeline of Retatrutide Side Effects
GI adverse events in Phase 2 were most frequent during initial dose escalation (weeks 1–8) and typically attenuated with continued use at stable maintenance doses [10]. Onset for some subjects occurred within hours of the first injection.
Dose-dependent GI adverse event rates from pooled Phase 2 safety data [10]: nausea — 2.69× to 4.27× higher than placebo rate; vomiting — 4.62× to 8.98× higher; diarrhea — 1.64× to 2.51× higher; constipation — 4.17× to 4.41× higher. All events were predominantly mild to moderate in severity.
At 12 mg (the highest studied Phase 2 dose), nausea was reported by up to approximately 60% of participants during titration; rates declined substantially at stable maintenance dose. Published trial participant guidance documents cite slower titration and small, frequent, low-fat meals as the primary mitigation strategies [10].
Risks and Adverse Events Observed in Trials
Common adverse events in Phase 2 (pooled): nausea (up to 60% at 12 mg during titration), diarrhea (15–33%), vomiting (21–26%), constipation (10–20%). Higher-dose cohorts experienced a greater GI burden during the titration period [10].
Uncommon findings in Phase 2 safety reviews: temporary ALT elevation in a subset of participants; mild resting heart rate increase of 2–4 bpm (class-level effect observed across GLP-1RA agents; clinical significance under ongoing evaluation) [20].
Lean mass considerations: glucagon receptor agonism can cause hypoaminoacidemia and muscle catabolism in preclinical rodent models through upregulation of hepatic amino acid catabolism pathways [14]. Phase 2 DXA data in humans did not demonstrate disproportionate lean mass loss relative to other anti-obesity agents [6]; the question of adequate dietary protein intake during retatrutide treatment is an active research area.
Serious Adverse Events: What Phase 2 and Phase 3 Reveal
Serious adverse events in Phase 2 were low-frequency. Pancreatitis was not significantly elevated above placebo in Phase 2 data. Thyroid C-cell effects observed in rodent GLP-1RA models were not detected in Phase 2 human biomarker data; calcitonin elevation led to participant exclusion in some TRIUMPH trial arms, and long-term thyroid monitoring continues in Phase 3 [20].
Phase 3 TRIUMPH-1 results showed higher-dose discontinuation rates (11.3% at 12 mg) driven primarily by GI events. Serious adverse events across trial arms were low; all three dose arms met primary and key secondary endpoints [5][17].
A dedicated cardiovascular outcomes trial (TRIUMPH-3) is ongoing; no CVOT data have been published as of May 2026.
Serious Adverse Events in Retatrutide Trials
The most significant tolerability concern identified in Phase 2 data is dose-dependent GI burden during titration, which drove the majority of discontinuations. Serious adverse events were uncommon and did not reveal clear signals above placebo for pancreatitis, thyroid malignancy, or cardiovascular harm in Phase 2 duration [20].
Class-level concerns carried over from other GLP-1RA agents include: potential thyroid C-cell effects (observed in GLP-1RA rodent models; not detected in Phase 2 human biomarker data; monitored in Phase 3); gallbladder-related events (class-level concern under active monitoring). Weight regain upon discontinuation is expected based on class biology — approximately 75.6% of lost weight may be regained after cessation per GLP-1RA class meta-analysis [18].
Managing GLP-1 Class Side Effects in Research Protocols
Research protocols and clinical trial participant guidance documents describe slower titration as the primary mitigation for GI adverse events. Published guidance also cites: small, frequent meals to reduce gastric distension-related nausea; avoiding high-fat, spicy, and strongly flavored foods during dose adjustment periods; maintaining adequate hydration [10].
For the retatrutide side effects burden at the 12 mg maintenance dose, the trial record shows attenuation over time at stable doses — events that peak during weeks 1–8 of escalation are substantially reduced at steady-state maintenance.